AIM AIM

AIM ImmunoTech Stock Price

0.40
-0.0051 (-1.26%)
Upgrade to Real-Time
Afterhours (Closed)
0.40
Volume 343,417
Bid Price
Ask Price
News -
Day High 0.4051

Low
0.3853

52 Week Range

High
1.51

Day Low 0.3853
Company Name Stock Ticker Symbol Market Type
AIM ImmunoTech Inc AIM AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0051 -1.26% 0.40 17:52:31
Open Price Low Price High Price Close Price Prev Close
0.40 0.3853 0.4051 0.405 0.4051
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
486 343,417 $ 0.3940774 $ 135,333 - 0.3853 - 1.51
Last Trade Time Type Quantity Stock Price Currency
20:00:00 285 $ 0.405 USD

Period:

Draw Mode:

AIM ImmunoTech Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 15.88M 39.69M 47.42M $ 134.00k $ - -0.40 -0.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 7.10%

more financials information »

AIM ImmunoTech News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AIM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.4330.470.38530.4280043133,872-0.033-7.62%
1 Month0.610.630.38530.4992345136,659-0.21-34.43%
3 Months0.680.680.38530.5433437131,287-0.28-41.18%
6 Months0.91481.050.38530.6837777142,698-0.5148-56.27%
1 Year1.441.510.38530.9776663278,080-1.04-72.22%
3 Years0.41988.750.38532.622,120,538-0.0198-4.72%
5 Years1.968.750.3812.592,004,545-1.56-79.59%

AIM ImmunoTech Description

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.